Tim I M Korevaar1,2,3, Layal Chaker4,5, Marco Medici6,4,5, Yolanda B de Rijke4,7, Vincent W V Jaddoe6,8,9, Eric A P Steegers10, Henning Tiemeier9,11, Theo J Visser4,5, Robin P Peeters6,4,5. 1. The Generation R Study Group, Rotterdam, The Netherlands. t.korevaar@erasmusmc.nl. 2. Department of Internal Medicine, Erasmus University Medical Center and/or Sophia Children's Hospital, Rotterdam, The Netherlands. t.korevaar@erasmusmc.nl. 3. Rotterdam Thyroid Center, Erasmus Medical Center, Rotterdam, The Netherlands. t.korevaar@erasmusmc.nl. 4. Department of Internal Medicine, Erasmus University Medical Center and/or Sophia Children's Hospital, Rotterdam, The Netherlands. 5. Rotterdam Thyroid Center, Erasmus Medical Center, Rotterdam, The Netherlands. 6. The Generation R Study Group, Rotterdam, The Netherlands. 7. Department of Clinical Chemistry, Erasmus University Medical Center and/or Sophia Children's Hospital, Rotterdam, The Netherlands. 8. Department of Pediatrics, Erasmus University Medical Center and/or Sophia Children's Hospital, Rotterdam, The Netherlands. 9. Department of Epidemiology, Erasmus University Medical Center and/or Sophia Children's Hospital, Rotterdam, The Netherlands. 10. Department of Obstetrics and Gynaecology, Erasmus University Medical Center and/or Sophia Children's Hospital, Rotterdam, The Netherlands. 11. Department of Child and Adolescent Psychiatry, Erasmus University Medical Center and/or Sophia Children's Hospital, Rotterdam, The Netherlands.
Abstract
AIM: We aimed to investigate TT4 physiological aspects and associations with clinical end-points. BACKGROUND: Total T4 (TT4) has been suggested as a marker for maternal thyroid function during pregnancy because as compared to FT4 (i) TT4 measurement is not affected by binding protein interference, (ii) TT4 is considered to be more stable from the second trimester onwards, and (iii) TT4 better reflects changes in the hypothalamic-pituitary-thyroid axis. However, this is based on data from small studies, and, more importantly, it is unknown whether TT4 is associated with adverse pregnancy or child outcomes. METHODS: We selected 5647 mother-child pairs from a large population-based prospective cohort with data on maternal TSH, FT4 and TT4 during early pregnancy (median 13·2 weeks, 95% range 9·8-17·6). We used multivariable (non)linear and logistic regression models to study the association of maternal TT4 with pre-eclampsia, premature delivery, birthweight and offspring IQ and compare the results with previously obtained results for FT4. RESULTS: The change of mean TT4 levels was 27·5% compared to 20·2% for FT4. There was a log-linear association of TT4 and FT4 with TSH, but the explained variability of TSH was much lower for TT4 than for FT4 (R-squared TT4: 2·5% vs 8·0% for FT4). In contrast to FT4, there was no independent association of maternal TT4 with pre-eclampsia, premature delivery, birthweight or offspring IQ. CONCLUSION: Maternal TT4 levels are highly variable in the first half of pregnancy and are poorly related to maternal TSH. This study shows that maternal TT4 levels are either not associated, or not better associated as compared to FT4, with adverse pregnancy or child outcomes. This suggests that the maternal TT4 is inferior to FT4 in the assessment of maternal thyroid function during the first half of pregnancy.
AIM: We aimed to investigate TT4 physiological aspects and associations with clinical end-points. BACKGROUND: Total T4 (TT4) has been suggested as a marker for maternal thyroid function during pregnancy because as compared to FT4 (i) TT4 measurement is not affected by binding protein interference, (ii) TT4 is considered to be more stable from the second trimester onwards, and (iii) TT4 better reflects changes in the hypothalamic-pituitary-thyroid axis. However, this is based on data from small studies, and, more importantly, it is unknown whether TT4 is associated with adverse pregnancy or child outcomes. METHODS: We selected 5647 mother-child pairs from a large population-based prospective cohort with data on maternal TSH, FT4 and TT4 during early pregnancy (median 13·2 weeks, 95% range 9·8-17·6). We used multivariable (non)linear and logistic regression models to study the association of maternal TT4 with pre-eclampsia, premature delivery, birthweight and offspring IQ and compare the results with previously obtained results for FT4. RESULTS: The change of mean TT4 levels was 27·5% compared to 20·2% for FT4. There was a log-linear association of TT4 and FT4 with TSH, but the explained variability of TSH was much lower for TT4 than for FT4 (R-squared TT4: 2·5% vs 8·0% for FT4). In contrast to FT4, there was no independent association of maternal TT4 with pre-eclampsia, premature delivery, birthweight or offspring IQ. CONCLUSION: Maternal TT4 levels are highly variable in the first half of pregnancy and are poorly related to maternal TSH. This study shows that maternal TT4 levels are either not associated, or not better associated as compared to FT4, with adverse pregnancy or child outcomes. This suggests that the maternal TT4 is inferior to FT4 in the assessment of maternal thyroid function during the first half of pregnancy.
Authors: Tim I M Korevaar; Daan Nieboer; Peter H L T Bisschop; Mariette Goddijn; Marco Medici; Layal Chaker; Yolanda B de Rijke; Vincent W V Jaddoe; Theo J Visser; Ewout W Steyerberg; Henning Tiemeier; Tanja G Vrijkotte; Robin P Peeters Journal: Clin Endocrinol (Oxf) Date: 2016-08-15 Impact factor: 3.478
Authors: Apostolos Chatzitomaris; Rudolf Hoermann; John E Midgley; Steffen Hering; Aline Urban; Barbara Dietrich; Assjana Abood; Harald H Klein; Johannes W Dietrich Journal: Front Endocrinol (Lausanne) Date: 2017-07-20 Impact factor: 5.555
Authors: Amber L Cathey; Deborah J Watkins; Zaira Y Rosario; Carmen M Vélez Vega; Bhramar Mukherjee; Marie S O'Neill; Rita Loch-Caruso; Akram N Alshawabkeh; José F Cordero; John D Meeker Journal: Front Endocrinol (Lausanne) Date: 2021-09-15 Impact factor: 6.055